نتایج جستجو برای: piperacillin

تعداد نتایج: 2563  

Journal: :Clinical journal of the American Society of Nephrology : CJASN 2016
Matthew S Shotwell Ross Nesbitt Phillip N Madonia Edward R Gould Michael J Connor Charbel Salem Olufemi A Aduroja Milen Amde Joseph J Groszek Peilin Wei Maria E Taylor Ashita J Tolwani William H Fissell

BACKGROUND AND OBJECTIVES Infection is the most common cause of death in severe AKI, but many patients receiving continuous RRT do not reach target antibiotic concentrations in plasma. Extended infusion of β-lactams is associated with improved target attainment in critically ill patients; thus, we hypothesized that extended infusion piperacillin-tazobactam would improve piperacillin target atta...

Journal: :Clinical journal of the American Society of Nephrology : CJASN 2012
Seth R Bauer Charbel Salem Michael J Connor Joseph Groszek Maria E Taylor Peilin Wei Ashita J Tolwani William H Fissell

BACKGROUND AND OBJECTIVES Current recommendations for piperacillin-tazobactam dosing in patients receiving continuous renal replacement therapy originate from studies with relatively few patients and lower continuous renal replacement therapy doses than commonly used today. This study measured the pharmacokinetic and pharmacodynamic characteristics of piperacillin-tazobactam in patients treated...

Journal: :Antimicrobial Agents and Chemotherapy 1978

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006
E J Bow C Rotstein G A Noskin M Laverdiere A P Schwarer B H Segal J F Seymour J Szer S Sanche

BACKGROUND The empirical treatment of febrile, neutropenic patients with cancer requires antibacterial regimens active against both gram-positive and gram-negative pathogens. This study was performed to demonstrate the noninferiority of monotherapy with piperacillin-tazobactam, compared with cefepime. METHODS We conducted a randomized-controlled, open-label, multicenter clinical trial among h...

Journal: :Antimicrobial agents and chemotherapy 2004
Thomas P Lodise Ben Lomaestro Keith A Rodvold Larry H Danziger George L Drusano

The primary objectives of this analysis were to determine which pharmacokinetic model most accurately describes the elimination pathways for piperacillin in the presence of tazobactam through population pharmacokinetic modeling and to characterize its pharmacodynamic profile. Once the optimal pharmacokinetic model was identified, Monte Carlo simulation of 10,000 subjects with ADAPT II was perfo...

Journal: :The new microbiologica 2011
Carlo Gagliotti Mario Sarti Carla Sabia Raffaele Gargiulo Gian Maria Rossolini Carmelina Carillo Carla Cassani Antonio Paolo Cipolloni Federica Pedna Maria Rita Rossi Silvia Storchi Incerti Giovanna Testa Claudia Venturelli Maria Luisa Moro

This study aimed to evaluate the accuracy of routine systems (Vitek2 cards AST-N022 and AST-N026; Kirby Bauer; Etest) for susceptibility testing of Pseudomonas aeruginosa to piperacillin and piperacillin-tazobactam. Vitek2 (card AST-N022) showed the worst performance; the other three methods (Vitek2 card AST-N026, Kirby-Bauer and E-test) performed comparably but never fulfilled the minimal stan...

Journal: :Antimicrobial agents and chemotherapy 2008
Elisa Bertazzoni Minelli Anna Benini Luigina Franco Claudio Bassi Paolo Pederzoli

Piperacillin-tazobactam was administered as a single dose (4.5 g intravenous) to five patients with stabilized external pancreatic fistula. The penetration into pancreatic juice was prompt, and inhibitory concentrations were achieved and maintained for different periods (0.5 to 6 h) according to bacterial susceptibility and patients' characteristics. Piperacillin and tazobactam showed superimpo...

Journal: :Antimicrobial agents and chemotherapy 2002
Silke C Mueller Jolanta Majcher-Peszynska Heiko Hickstein Astrid Francke Annette Pertschy Martin Schulz Ralf Mundkowski Bernd Drewelow

The pharmacokinetics of piperacillin-tazobactam were investigated in eight anuric intensive care patients treated by continuous venovenous hemodialysis (CVVHD). The elimination half-life of piperacillin was 4.3 +/- 1.2 h, and that of tazobactam was 5.6 +/- 1.3 h. The contribution of CVVHD to the overall elimination was relevant (>25%) for both drugs.

Journal: :International Journal of Basic & Clinical Pharmacology 2018

Journal: :Journal of Clinical Medicine Research 2009

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید